Potent inhibition of Hendra virus infection via RNA interference and poly I:C immune activation

作者: Jana L. McCaskill , Glenn A. Marsh , Paul Monaghan , Lin-Fa Wang , Timothy Doran

DOI: 10.1371/JOURNAL.PONE.0064360

关键词:

摘要: Hendra virus (HeV) is a highly pathogenic zoonotic paramyxovirus that causes fatal disease in wide range of species, including humans. HeV was first described Australia 1994, and has continued to re-emerge with increasing frequency. significant concern human health due its high mortality rate, emergence, absence vaccines limited post exposure therapies. Here we investigate the use RNA interference (RNAi) based therapeutics targeting conjunction TLR3 agonist Poly I:C show they are potent inhibitors infection vitro. We found short interfering RNAs (siRNAs) abundantly expressed N, P M genes caused over 95% reduction titre, protein mRNA. Furthermore, combination siRNA had an additive effect suppressing infection. Our results demonstrate for time RNAi type I interferon stimulation effective replication vitro may provide therapy this lethal, pathogen.

参考文章(36)
Linda A Selvey, Rachel M Wells, Joseph G McCormack, Anthony J Ansford, Keith Murray, Russell J Rogers, Peter S Lavercombe, Paul Selleck, John W Sheridan, Infection of humans and horses by a newly described morbillivirus. The Medical Journal of Australia. ,vol. 162, pp. 642- 645 ,(1995) , 10.5694/J.1326-5377.1995.TB126050.X
Megan L Shaw, Adolfo García-Sastre, Peter Palese, Christopher F Basler, None, Nipah Virus V and W Proteins Have a Common STAT1-Binding Domain yet Inhibit STAT1 Activation from the Cytoplasmic and Nuclear Compartments, Respectively Journal of Virology. ,vol. 78, pp. 5633- 5641 ,(2004) , 10.1128/JVI.78.11.5633-5641.2004
Maria Buti, Rafael Esteban, 1990-2010: two decades of interferon-based therapy. Clinics in Liver Disease. ,vol. 15, pp. 473- 482 ,(2011) , 10.1016/J.CLD.2011.05.007
Christopher C Broder, Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Current Opinion in Virology. ,vol. 2, pp. 176- 187 ,(2012) , 10.1016/J.COVIRO.2012.02.016
John C. Burnett, John J. Rossi, Katrin Tiemann, Current progress of siRNA/shRNA therapeutics in clinical trials Biotechnology Journal. ,vol. 6, pp. 1130- 1146 ,(2011) , 10.1002/BIOT.201100054
J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, R. Meyers, J. Gollob, A. Vaishnaw, A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 8800- 8805 ,(2010) , 10.1073/PNAS.0912186107
Stephen Luby, Mahmudur Rahman, M. Hossain, Lauren Blum, M. Husain, Emily Gurley, Rasheda Khan, Be-Nazir Ahmed, Shafiqur Rahman, Nazmun Nahar, Eben Kenah, James Comer, Thomas Ksiazek, Foodborne transmission of Nipah virus, Bangladesh. Emerging Infectious Diseases. ,vol. 12, pp. 1888- 1894 ,(2006) , 10.3201/EID1212.060732
Norliana Khairuddin, Michael P Gantier, Stephen J Blake, Sherry Y Wu, Mark A Behlke, Bryan RG Williams, Nigel AJ McMillan, siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo Immunology and Cell Biology. ,vol. 90, pp. 187- 196 ,(2012) , 10.1038/ICB.2011.19
Daniel Boden, Oliver Pusch, Frederick Lee, Lynne Tucker, Bharat Ramratnam, Human Immunodeficiency Virus Type 1 Escape from RNA Interference Journal of Virology. ,vol. 77, pp. 11531- 11535 ,(2003) , 10.1128/JVI.77.21.11531-11535.2003